January 23, 2019

Subject: ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated] is now available to pediatric patients <12 years of age with hemophilia A through Canadian Blood Services (CBS).

Dear Healthcare Professional,

Takeda Canada is delighted to notify you that ADYNOVATE is available to adults, adolescents and pediatric patients <12 years of age with hemophilia A.

ADYNOVATE is indicated in patients with hemophilia A (congenital factor VIII deficiency) for:
1. Control and prevention of bleeding episodes
2. Prophylaxis to prevent or reduce the frequency of bleeding episodes
3. Perioperative management

ADYNOVATE is now available through Canadian Blood Services for adults and pediatric patients <12 years of age with hemophilia A. In addition to Canada, ADYNOVATE is available for use in pediatric patients in the US, Japan, Switzerland and Colombia.

Consult the ADYNOVATE Product Monograph at https://www.shirecanada.com/-/media/shire/shireglobal/shirecanada/pdf/Adynovate-pm-en.pdf for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available through our medical department. Call us at 1-800-268-2772.

Yours sincerely,

Anand Janack
Franchise Head, Hematology
Shire Pharma Canada ULC
Shire is now part of Takeda

Takeda and the Takeda Logo are trademarks of Takeda Pharmaceutical Company Limited, used under license.
ADYNOVATE® is a trademark of Shire Pharmaceutical Holdings Ireland, a wholly owned, indirect subsidiary of Takeda Pharmaceutical Company Limited. Shire Pharma Canada ULC, now part of Takeda, remains the market authorization holder.